Josef S. Smolen – författare

Covering both the scientific basis of rheumatology and practical, clinical information for rheumatologists and trainees, Rheumatology, 8th Edition, remains a leading text in this fast-changing field. Dr. Marc Hochberg and his team of worldwide editors and authors keep you abreast of recent advances in the field- all in a user-friendly, accessible manner. Fully updated from cover to cover, this two-volume text is designed to meet the needs of all practicing and academic rheumatologists as well as arthritis-related health care professionals and scientists interested in rheumatic and musculoskeletal diseases.Covers the epidemiology, pathogenesis, clinical manifestations, therapeutic approach, and management of all major as well as rarely encountered rheumatic and musculoskeletal diseases.Discusses clinical examination, imaging principles, differential diagnosis, established and novel therapies, perioperative evaluation, pain management, basic science, and genetics of rheumatic and musculoskeletal diseases.Uses a consistent, logical, reader-friendly format with templated chapters, concise text, and large-scale, state-of-the-art illustrations for efficient visual reference.Contains new chapters covering pre-clinical disease and how to address these patients, common comorbidities in rheumatoid arthritis; emerging therapies for systemic sclerosis; immune mediated complications of checkpoint inhibitors; the epidemiology of COVID-19 and rheumatic and musculoskeletal diseases, emerging treatments for osteoarthritis, and big data analytics.Provides updates to key topics such as systems biology and its impact on our understanding of the pathogenesis of rheumatic and musculoskeletal diseases, the microbiome in rheumatic musculoskeletal diseases, how to manage chronic pain in the patient with a rheumatic disease, drugs and reproductive health, and emerging therapies for patients with RA, SLE, spondyloarthritis, inflammatory muscle disease, and vasculitis.Shares the knowledge and expertise of numerous new contributing authors, as well as new co-editor Dr. Désirée van der Heijde, who is an expert in psoriatic arthritis, spondyloarthritis, imaging, and clinical epidemiology.Provides access to concise videos depicting the use of ultrasound for diagnosis and treatment.Enhanced eBook version included with purchase. Your enhanced eBook allows you to access all of the text, figures, and references from the book on a variety of devices. If you encounter issues with your eBook please contact Elsevier eBook+ support via textbookscom.support@elsevier.com.

Written and edited by international leaders in the field, Rheumatology, 9th Edition, seamlessly blends the latest scientific advances in rheumatology with real-world clinical insights, making it an essential resource for rheumatology specialists and fellows. This comprehensive, two-volume reference uses an easy-to-follow, templated format with concise text and cutting-edge illustrations, covering key topics such as epidemiology, physical examination, pathogenesis, clinical features, therapeutic strategies, and management of both common and rare rheumatic diseases. New contributing authors, new content throughout, and up-to-date coverage of new breakthroughs in the treatment of lupus, rheumatoid arthritis, and more keep you abreast of recent changes in this fast-changing field.

Targeted therapies of rheumatic diseases have become a reality and have completely changed patient care as well as patient expectations. Initial success with therapies aimed at blocking TNF and IL-1 has stimulated the development of additional targeted approaches focused on other cytokines as well as specific cells and pathways involved in the pathogenesis of rheumatic diseases.Along with the clinical success of some of these targeted approaches, new information has been generated from their application concerning the pathophysiologic mechanisms underlying rheumatic diseases and, as a result, new targets have been identified.The ongoing dialogue between basic scientists, clinical investigators, metrologists and clinicians remains an essential component for the further development, refinement, integration and optimization of targeted therapies of the rheumatic diseases. The goal of this volume is to provide comprehensive, up to date information on all aspects of the rapidly evolving development of targeted therapies of the rheumatic diseases to foster further advances to improve therapy of patients with these conditions.Targeted Therapies in Rheumatology established itself as an excellent reference for all those needing to know about the clinical implications of new drugs and developments for patients suffering from rheumatoid arthritis. This volume takes up the further developments that have occurred in several of the drug therapies covered in the first volume, as well as looking at the latest areas of promising research.

More than 140 years ago, lupus erythematosus (LE) was recognized as a disease entity by clinicians working in the field of dermatology, which had only recently become an independent medical discipline. Soon after cutaneous lupus was first reported, it was realized that, apart from the skin, the disease could involve other organs and thus be systemic in nature. The latter observations were first made by MORITZ KApOSI [1], whose work has attracted renewed attention re­ cently and who succeeded FERDINAND VON HEBRA to the chair of dermatology at the Medical Faculty in Vienna. The early description of lupus erythematosus in both its cutaneous and systemic manifes­ tations was thus intimately associated with Vienna and its Medical School. The next phase in the study of lupus was characterized by an in­ crease in knowledge of the type and extent of organ involvement. The work by OSLER [2], LIBMANN and SACKS [3], and KLEMPERER [4] best represents these advances. The increase in clinical knowledge of LE finally led to DUBOIS' famous monograph [5], which was pub­ lished at a time of renewed interest in SLE, elicited by the descrip­ tion by HARGRAVES et al. [6] of the LE-cell phenomenon. A more detailed analysis of this finding revealed that the disease was charac­ terized by an abnormal immune response, although its pathogenetic implications were still unclear.